Progressive multifocal leukoencephalopathy after natalizumab discontinuation: Few and true?

Annals of Neurology

Volumn 75, Issue 3, 2014, Pages 462-

  Wattjes, Mike P ^a   Killestein, Joep ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB;

CD4+ T LYMPHOCYTE; CLINICAL ASSESSMENT; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; HUMAN; LETTER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MULTIPLE SCLEROSIS; WITHHOLDING TREATMENT;

EID: 84897989231     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24110     Document Type: Letter

References (5)

1. Fine AJ, Sorbello A, Kortepeter C, Scarazzini L,. Progressive multifocal leukoencephalopathy after natalizumab discontinuation. Ann Neurol 2013; Nov 16. doi: 10.1002/ana.24051. [Epub ahead of print]
2. Rispens T, Vennegoor A, Wolbink GJ, et al. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped. Mult Scler 2012; 18: 899-901.
3. Yousry TA, Pelletier D, Cadavid D, et al. MRI pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2012; 72: 779-787.
4. Wattjes MP, Richert ND, Killestein J, et al. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler 2013; 19: 1826-1840.
5. Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 2013; 80: 1430-1438.